harmonizing between data driven & knowledge based approaches
A Machine Learning Model trained by Network Analysis
Drug development is a high-risk endeavor. Nearly 90% of potential drug candidates that enter phase I trials fail to reach the clinic. This problem isn't new to the pharma world. Every year, seemingly endless amounts of resources are wasted on drug candidates of which the majority never reach the market.
Our platform will transform the pharma industry. Capable of ingesting preclinical data of all modalities across multiple species, our platform aggregates all data to identify common and unique biological features. Our solution applies proprietary technology, harnessing the power of network analysis and machine learning approaches.
BiolomiX's unique method harmonizes between data driven and knowledge-based approaches. Proof of concepts studies have shown that our approach is more accurate and effective than other methods. At the core of our platform sits a patented approach – our secret sauce - determining biological activity of a biological feature. This approach overcomes a key caveat of conventional methods by emphasizing biological activity, as opposed to presence, generating a new data type, we call “activity score”.
Our platform accurately predicts efficacy and safety of a drug candidate and suggests validation experiments. As a result, pharma companies can significantly de-risk the decision of moving a candidate from preclincal to clinical trials.
